A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma (NCT04485949)

🧪 Interventions in This Study

• IGV-001 Cell Immunotherapy (COMBINATION_PRODUCT)
• Placebo (COMBINATION_PRODUCT)
• SOC: Temozolomide (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (23 Sites)

• Mayo Clinic - Jacksonville — Jacksonville, Florida
• Tufts Medical Center — Boston, Massachusetts
• Henry Ford Health System — Detroit, Michigan
• Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire
• John Theurer Cancer Center At Hackensack UMC — Hackensack, New Jersey
• Jersey Shore University Medical Center — Neptune City, New Jersey
• Northwell Health at North Shore University Hospital — Manhasset, New York
• David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center — New York, New York
• Icahn School of Medicine at Mount Sinai — New York, New York
• Columbia University Medical Center — New York, New York
• Weill Cornell Medicine — New York, New York
• Lenox Hill Hospital — New York, New York
• Montefiore Medical Center — The Bronx, New York
• Westchester Medical Center — Valhalla, New York
• University of North Carolina (UNC) - Chapel Hill — Chapel Hill, North Carolina
• UC Health — Cincinnati, Ohio
• The Ohio State University (OSU) Wexner Medical Center — Columbus, Ohio
• The Pennsylvania State University (Penn State) Milton S. Hershey Medical Center — Hershey, Pennsylvania
• Thomas Jefferson University — Philadelphia, Pennsylvania
• University of Pennsylvania — Philadelphia, Pennsylvania
• Rhode Island Hospital — Providence, Rhode Island
• West Virginia University — Morgantown, West Virginia
• University of Wisconsin - Madison — Madison, Wisconsin

📞 Contact the Study Coordinator

Phone: (800) 664-4580

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Glioblastoma

• Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma — Milwaukee, Wisconsin
• A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent. — New York, New York
• A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors — San Francisco, California
• Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma — Phoenix, Arizona
• A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma — Birmingham, Alabama
• Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma — Fairbanks, Alaska

Explore by condition: All Glioblastoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.